503 related articles for article (PubMed ID: 12381242)
1. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.
Sheth K; Borker R; Emmett A; Rickard K; Dorinsky P
Pharmacoeconomics; 2002; 20(13):909-18. PubMed ID: 12381242
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.
O'Connor RD; Nelson H; Borker R; Emmett A; Jhingran P; Rickard K; Dorinsky P
Pharmacoeconomics; 2004; 22(12):815-25. PubMed ID: 15294013
[TBL] [Abstract][Full Text] [Related]
3. Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.
Pieters WR; Wilson KK; Smith HC; Tamminga JJ; Sondhi S
Treat Respir Med; 2005; 4(2):129-38. PubMed ID: 15813665
[TBL] [Abstract][Full Text] [Related]
4. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
O'Connor RD; Stanford R; Crim C; Yancey SW; Edwards L; Rickard KA; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Dec; 93(6):581-8. PubMed ID: 15609769
[TBL] [Abstract][Full Text] [Related]
5. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2003; 21(13):951-89. PubMed ID: 12959627
[TBL] [Abstract][Full Text] [Related]
6. [Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children].
Rely K; McQuire SE; Alexandre PK; Escudero GS
Value Health; 2011; 14(5 Suppl 1):S43-7. PubMed ID: 21839898
[TBL] [Abstract][Full Text] [Related]
7. Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves.
Borker R; Emmett A; Jhingran P; Rickard K; Dorinsky P
Ann Allergy Asthma Immunol; 2005 Aug; 95(2):181-9. PubMed ID: 16136769
[TBL] [Abstract][Full Text] [Related]
8. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
Markham A; Jarvis B
Drugs; 2000 Nov; 60(5):1207-33. PubMed ID: 11129128
[TBL] [Abstract][Full Text] [Related]
9. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma.
Pearlman DS; White MV; Lieberman AK; Pepsin PJ; Kalberg C; Emmett A; Bowers B; Rickard KA; Dorinsky P
Ann Allergy Asthma Immunol; 2002 Feb; 88(2):227-35. PubMed ID: 11868930
[TBL] [Abstract][Full Text] [Related]
10. Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis.
Balkrishnan R; Nelsen LM; Kulkarni AS; Pleasants RA; Whitmire JT; Schechter MS
J Asthma; 2005 Feb; 42(1):35-40. PubMed ID: 15801326
[TBL] [Abstract][Full Text] [Related]
11. Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone.
Calhoun WJ; Nelson HS; Nathan RA; Pepsin PJ; Kalberg C; Emmett A; Rickard KA; Dorinsky P
Am J Respir Crit Care Med; 2001 Sep; 164(5):759-63. PubMed ID: 11549529
[TBL] [Abstract][Full Text] [Related]
12. Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety.
Lenney W; McKay AJ; Tudur Smith C; Williamson PR; James M; Price D;
Health Technol Assess; 2013 Feb; 17(4):1-218. PubMed ID: 23380178
[TBL] [Abstract][Full Text] [Related]
13. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
[TBL] [Abstract][Full Text] [Related]
14. Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma.
Menendez R; Stanford RH; Edwards L; Kalberg C; Rickard K
Pharmacoeconomics; 2001; 19(8):865-74. PubMed ID: 11596838
[TBL] [Abstract][Full Text] [Related]
15. Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.
Markham A; Adkins JC
Pharmacoeconomics; 2000 Dec; 18(6):591-608. PubMed ID: 11227397
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.
Doull I; Price D; Thomas M; Hawkins N; Stamuli E; Tabberer M; Gosden T; Rudge H
Curr Med Res Opin; 2007 May; 23(5):1147-59. PubMed ID: 17519082
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW
Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652
[TBL] [Abstract][Full Text] [Related]
18. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study.
Ilowite J; Webb R; Friedman B; Kerwin E; Bird SR; Hustad CM; Edelman JM
Ann Allergy Asthma Immunol; 2004 Jun; 92(6):641-8. PubMed ID: 15237766
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
Maspero J; Guerra F; Cuevas F; Gutierrez JP; Soto-Ramos M; Anderton S; Mechali D; Chan R; Pedersen S
Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
[TBL] [Abstract][Full Text] [Related]
20. Invalid and irrelevant comparisons: apples or oranges?
Currie GP; Carter K
Ann Allergy Asthma Immunol; 2006 Feb; 96(2):379. PubMed ID: 16498865
[No Abstract] [Full Text] [Related]
[Next] [New Search]
